Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$0.7172
At close: Mar 25, 7:55 PM EDT
$0.7300
0.011.78%
After Hours: 7:55 PM EDT
Comments
Loading...
ALX Oncology Holdings Analyst Ratings and Price Targets | NASDAQ:ALXO | Benzinga
ALX Oncology Holdings Inc has a consensus price target of $10.39 based on the ratings of 8 analysts. The high is $34 issued by Credit Suisse on March 10, 2023. The low is $1.5 issued by Stifel on March 7, 2025. The 3 most-recent analyst ratings were released by Stifel, HC Wainwright & Co., and Piper Sandler on March 7, 2025, March 7, 2025, and March 6, 2025, respectively. With an average price target of $5.17 between Stifel, HC Wainwright & Co., and Piper Sandler, there's an implied 607.76% upside for ALX Oncology Holdings Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Stifel
HC Wainwright & Co.
Piper Sandler
Jefferies
UBS
1calculated from analyst ratings
Analyst Ratings for ALX Oncology Holdings
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/07/2025 | Buy Now | 105.48% | Stifel | Bradley Canino38% | $3 → $1.5 | Maintains | Hold | Get Alert |
| 03/07/2025 | Buy Now | 584.93% | HC Wainwright & Co. | Swayampakula Ramakanth50% | $5 → $5 | Reiterates | Buy → Buy | Get Alert |
| 03/06/2025 | Buy Now | 1132.88% | Piper Sandler | Christopher Raymond57% | $8 → $9 | Maintains | Overweight | Get Alert |
| 03/06/2025 | Buy Now | 310.96% | Jefferies | Michael Yee56% | $2 → $3 | Upgrade | Hold → Buy | Get Alert |
| 01/27/2025 | Buy Now | 201.37% | UBS | Colin Bristow41% | $4 → $2.2 | Maintains | Buy | Get Alert |
| 01/24/2025 | Buy Now | — | Cantor Fitzgerald | Li Watsek41% | — | Reiterates | Overweight → Overweight | Get Alert |
| 01/24/2025 | Buy Now | 584.93% | HC Wainwright & Co. | Swayampakula Ramakanth50% | $25 → $5 | Maintains | Buy | Get Alert |
| 12/19/2024 | Buy Now | 173.97% | Jefferies | Michael Yee56% | $12 → $2 | Downgrade | Buy → Hold | Get Alert |
| 12/18/2024 | Buy Now | — | Cantor Fitzgerald | Li Watsek41% | — | Reiterates | Overweight → Overweight | Get Alert |
| 12/18/2024 | Buy Now | 3324.66% | HC Wainwright & Co. | Swayampakula Ramakanth50% | $25 → $25 | Reiterates | Buy → Buy | Get Alert |
| 11/12/2024 | Buy Now | — | Cantor Fitzgerald | Li Watsek41% | — | Reiterates | → Overweight | Get Alert |
| 08/16/2024 | Buy Now | 447.95% | UBS | Colin Bristow41% | $25 → $4 | Maintains | Buy | Get Alert |
| 08/13/2024 | Buy Now | 3324.66% | HC Wainwright & Co. | Swayampakula Ramakanth50% | $25 → $25 | Reiterates | Buy → Buy | Get Alert |
| 08/12/2024 | Buy Now | — | Cantor Fitzgerald | Li Watsek41% | — | Reiterates | → Overweight | Get Alert |
| 08/09/2024 | Buy Now | 310.96% | Stifel | Bradley Canino38% | $5 → $3 | Reiterates | Hold → Hold | Get Alert |
| 08/01/2024 | Buy Now | 584.93% | Stifel | Bradley Canino38% | $14 → $5 | Maintains | Hold | Get Alert |
| 08/01/2024 | Buy Now | 3324.66% | HC Wainwright & Co. | Swayampakula Ramakanth50% | $25 → $25 | Reiterates | Buy → Buy | Get Alert |
| 06/10/2024 | Buy Now | 3324.66% | HC Wainwright & Co. | Swayampakula Ramakanth50% | $25 → $25 | Reiterates | Buy → Buy | Get Alert |
| 05/29/2024 | Buy Now | — | Cantor Fitzgerald | Li Watsek41% | — | Reiterates | → Overweight | Get Alert |
| 04/12/2024 | Buy Now | — | Cantor Fitzgerald | Li Watsek41% | — | Reiterates | → Overweight | Get Alert |
| 04/10/2024 | Buy Now | 2639.73% | HC Wainwright & Co. | Swayampakula Ramakanth50% | $20 → $20 | Reiterates | Buy → Buy | Get Alert |
| 03/11/2024 | Buy Now | 2639.73% | HC Wainwright & Co. | Swayampakula Ramakanth50% | $17.5 → $20 | Maintains | Buy | Get Alert |
| 03/08/2024 | Buy Now | 1817.81% | Stifel | Bradley Canino38% | $10 → $14 | Downgrade | Buy → Hold | Get Alert |
| 03/08/2024 | Buy Now | 2776.71% | Piper Sandler | Christopher Raymond57% | $11 → $21 | Maintains | Overweight | Get Alert |
| 12/08/2023 | Buy Now | 2365.75% | Jefferies | Michael Yee56% | $8 → $18 | Upgrade | Hold → Buy | Get Alert |
| 11/14/2023 | Buy Now | 1269.86% | Stifel | Bradley Canino38% | $11 → $10 | Maintains | Buy | Get Alert |
| 10/11/2023 | Buy Now | 1406.85% | Piper Sandler | Christopher Raymond57% | $8 → $11 | Maintains | Overweight | Get Alert |
| 10/04/2023 | Buy Now | 3598.63% | UBS | Colin Bristow41% | $29 → $27 | Maintains | Buy | Get Alert |
| 10/04/2023 | Buy Now | 3050.68% | Cantor Fitzgerald | Li Watsek41% | $18 → $23 | Maintains | Overweight | Get Alert |
| 10/03/2023 | Buy Now | 2297.26% | HC Wainwright & Co. | Swayampakula Ramakanth50% | $16 → $17.5 | Reiterates | Buy → Buy | Get Alert |
| 09/12/2023 | Buy Now | 2365.75% | Cantor Fitzgerald | Alethia Young76% | → $18 | Reiterates | Overweight → Overweight | Get Alert |
| 09/07/2023 | Buy Now | 2365.75% | Cantor Fitzgerald | Alethia Young76% | → $18 | Reinstates | Overweight → Overweight | Get Alert |
| 08/14/2023 | Buy Now | 2365.75% | Cantor Fitzgerald | Alethia Young76% | $22 → $18 | Maintains | Overweight | Get Alert |
| 08/11/2023 | Buy Now | 2365.75% | Cantor Fitzgerald | Alethia Young76% | $22 → $18 | Maintains | Overweight | Get Alert |
| 08/11/2023 | Buy Now | 995.89% | Piper Sandler | Christopher Raymond57% | $48 → $8 | Maintains | Overweight | Get Alert |
| 08/11/2023 | Buy Now | 2091.78% | HC Wainwright & Co. | Swayampakula Ramakanth50% | $30 → $16 | Maintains | Buy | Get Alert |
| 07/24/2023 | Buy Now | 2913.7% | Cantor Fitzgerald | Alethia Young76% | → $22 | Reiterates | Overweight → Overweight | Get Alert |
| 05/12/2023 | Buy Now | 4009.59% | HC Wainwright & Co. | Swayampakula Ramakanth50% | → $30 | Reiterates | Buy → Buy | Get Alert |
| 03/15/2023 | Buy Now | 3872.6% | UBS | Colin Bristow41% | $31 → $29 | Maintains | Buy | Get Alert |
| 03/10/2023 | Buy Now | 4557.53% | Credit Suisse | Tiago Fauth42% | $38 → $34 | Maintains | Outperform | Get Alert |
| 03/10/2023 | Buy Now | 4009.59% | HC Wainwright & Co. | Swayampakula Ramakanth50% | $65 → $30 | Maintains | Buy | Get Alert |
| 11/09/2022 | Buy Now | 8804.11% | HC Wainwright & Co. | Swayampakula Ramakanth50% | $80 → $65 | Maintains | Buy | Get Alert |
| 08/09/2022 | Buy Now | 5105.48% | Credit Suisse | Tiago Fauth42% | $43 → $38 | Maintains | Outperform | Get Alert |
| 06/06/2022 | Buy Now | 2091.78% | Stifel | Bradley Canino38% | $35 → $16 | Maintains | Buy | Get Alert |
| 05/19/2022 | Buy Now | 6475.34% | Piper Sandler | Christopher Raymond57% | $70 → $48 | Maintains | Overweight | Get Alert |
FAQ
What is the target price for ALX Oncology Holdings (ALXO) stock?
The latest price target for ALX Oncology Holdings (NASDAQ:ALXO) was reported by Stifel on March 7, 2025. The analyst firm set a price target for $1.50 expecting ALXO to rise to within 12 months (a possible 105.48% upside). 21 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for ALX Oncology Holdings (ALXO)?
The latest analyst rating for ALX Oncology Holdings (NASDAQ:ALXO) was provided by Stifel, and ALX Oncology Holdings maintained their hold rating.
When was the last upgrade for ALX Oncology Holdings (ALXO)?
The last upgrade for ALX Oncology Holdings Inc happened on March 6, 2025 when Jefferies raised their price target to $3. Jefferies previously had a hold for ALX Oncology Holdings Inc.
When was the last downgrade for ALX Oncology Holdings (ALXO)?
The last downgrade for ALX Oncology Holdings Inc happened on December 19, 2024 when Jefferies changed their price target from $12 to $2 for ALX Oncology Holdings Inc.
When is the next analyst rating going to be posted or updated for ALX Oncology Holdings (ALXO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ALX Oncology Holdings, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ALX Oncology Holdings was filed on March 7, 2025 so you should expect the next rating to be made available sometime around March 7, 2026.
Is the Analyst Rating ALX Oncology Holdings (ALXO) correct?
While ratings are subjective and will change, the latest ALX Oncology Holdings (ALXO) rating was a maintained with a price target of $3.00 to $1.50. The current price ALX Oncology Holdings (ALXO) is trading at is $0.73, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.